The study of markers of endothelial dysfunction in metabolic syndrome

Hormone Molecular Biology and Clinical Investigation

Volumn 24, Issue 3, 2015, Pages 131-136

  Ahirwar, Ashok Kumar ^a   Jain, Anju ^b   Singh, Archana ^a   Goswami, Binita ^b   Bhatnagar, M K ^b   Bhatacharjee, Jayashree ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

^c SAFDARJUNG HOSPITAL   (India)

Author keywords

Endothelin; Insulin; Metabolic syndrome; NO; Plasminogen activator inhibitor 1

Indexed keywords

BIOLOGICAL MARKER; ELECTROLYTE; ENDOTHELIN; INSULIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN;

ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMICAL ANALYSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; EARLY DIAGNOSIS; ELECTROLYTE BLOOD LEVEL; ENDOTHELIAL DYSFUNCTION; HEMATOLOGICAL PROCEDURE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; BLOOD; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BIOMARKERS; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN RESISTANCE; MAP KINASE SIGNALING SYSTEM; METABOLIC SYNDROME X; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84958759070     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2015-0039     Document Type: Article

References (18)

1. Ahirwar AK, Jain A, Goswami B, Bhatnagar MK, Bhatacharjee J. Imbalance between protective (adiponectin) and prothrombotic (Plasminogen Activator Inhibitor-1) adipokines in metabolic syndrome. Diab Met Syndr: Clin Res Rev 2014;8:152-5.
2. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 2011;18:139-43.
3. Grazyna S. Pro-inflammatory and prothrombotic factors and metabolic syndrome. eJIFCC 2007,18 (1) [Cited 2011 sep 19] Available from: http://www.ifcc.org/index.asp?cat=Publications &scat=eJIFCC-&suba=Vol-18-No-1&subx=Proinflammatory%20 and%20prothrombotic%20Factors%20and%20Metabolic%20 Sndrome%20&zip=1&dove=1&zona=full&numero=&aq=1.
4. Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 2004;109:2-4.
5. Sarafidis PA, Bakris GL. Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007;92:379-85.
6. Alessi MC,Vague IJ. PAI-1 and the Metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200-7.
7. Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009;60:19-24.
8. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
9. Mathew F, Glenda J, Jack L. Quantification of nitric and nitrate in extracellular fluids. Metho Enzymol 1996;268:237-46.
10. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
11. Sun YX, Hu SJ, Zhang XH, Sun J, Zhu CH, Zhang ZJ. Plasma levels of vWF and NO in patients with metabolic syndrome and their relationship with metabolic disorders. Zhejiang Da Xue Xue Bao Yi Xue Ban 2006;35:315-8.
12. Cai H, Harrison DG, Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000;87:840-4.
13. Donatelli M, Hoffmann E, Colletti I, Andolina G, Russo V, Bucalo ML, Valenti TM, Compagno V, Cataldo MG, Morici ML. Circulating endothelin- 1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol 1996;33: 246-8.
14. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. American Diabetes Association. Diabetes 2007;56:728-34.
15. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250-3.
16. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysac-charide. J Clin Invest 1996;97:37-46.
17. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006;30:1308-14.
18. Chou YY, Sheu WH, Tang YJ, Chen YM, Liao SC, Chuang YW, Lin CS, Chen DY. Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan. Arch Gerontol Geriatr 2009;49(Suppl 2):41-5.